Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
AstraZeneca Tunes Drug Portfolio
by Jean-François Tremblay
August 3, 2015
| A version of this story appeared in
Volume 93, Issue 31
AstraZeneca and Fujifilm Kyowa Kirin Biologics (FKB) are forming a 50-50 joint venture to develop a biosimilar of Avastin, a Genentech cancer drug. The new venture will pay $45 million to FKB for a biologic that is undergoing Phase I clinical trials in Europe. FKB is a biosimilars joint venture set up in 2012 by Fujifilm and Kyowa Hakko Kirin. Separately, AstraZeneca will get up to $300 million for selling Genzyme the rights to Caprelsa, a drug for treating aggressive and symptomatic medullary thyroid carcinoma, a rare disease. Caprelsa registered sales of $48 million in 2014.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X